Sinopia Biosciences Awarded NIH Grant to Support Development of Parkinson’s Disease Pipeline

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

We are pleased to receive funding from the NIH to support the advancement of our Parkinsons disease program towards the clinic, said Iman Famili, Ph.D., President and Chief Executive Officer of Sinopia Biosciences.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, September 27, 2021
Information
Tags: 
Biotechnology, Pharmaceutical, Health, Clinical Trials, Neurological disorder, SBIR, Research, National, National Institute of Neurological Disorders and Stroke, Therapy, NINDS, Patient, Caregiver, List of life sciences, Pharmacology, Lists of diseases, Disease, PD, National Institute, IND, NIH, Machine learning, Levodopa-induced dyskinesia, L-DOPA, Pharmaceutical industry
Geotags: 
United States, California
⚠generated by AI ↴
Summary
Key Points: 
  • We are pleased to receive funding from the NIH to support the advancement of our Parkinsons disease program towards the clinic, said Iman Famili, Ph.D., President and Chief Executive Officer of Sinopia Biosciences.
  • Parkinsons disease affects nearly 7 million people worldwide and is the fastest growing neurological disorder in the world, with the number of patients expected to double by 2040.
  • Its a disease that imposes heavy burdens on patients and caregivers, particularly because current treatments are not optimal and have serious long-term liabilities with chronic use that must be addressed.
  • Sinopia Biosciences, Inc. is a clinical-stage biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform.


Sinopia Biosciences, Inc., a clinical-stage biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform, has been awarded a $3.3 million Fast-Track SBIR grant from the National Institute of Neurological Disorders and Stroke (NINDS), as part of the National Institutes of Health (NIH), to fund investigational new drug (IND)-enabling studies for Sinopia’s small molecule candidate for Parkinson’s disease (PD).

“We are pleased to receive funding from the NIH to support the advancement of our Parkinson’s disease program towards the clinic,” said Iman Famili, Ph.D., President and Chief Executive Officer of Sinopia Biosciences. “Parkinson’s disease affects nearly 7 million people worldwide and is the fastest growing neurological disorder in the world, with the number of patients expected to double by 2040. It’s a disease that imposes heavy burdens on patients and caregivers, particularly because current treatments are not optimal and have serious long-term liabilities with chronic use that must be addressed.”

The proprietary small molecule has a novel mechanism of action and was identified using Sinopia’s LEarn And DiScover (LEADS) platform, a next-generation drug discovery engine driven by machine learning and multi-omics network analysis to pinpoint and prioritize targets and compounds to move into development. In multiple preclinical rodent and non-human primate studies, Sinopia’s drug candidate demonstrated a unique and potentially transformative pharmacology for treating both the symptoms of Parkinson’s disease and also the complications of levodopa, (i.e., levodopa-induced dyskinesia).

Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke of the National Institutes of Health under Award Number R44NS124398. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About Sinopia Biosciences

Sinopia Biosciences, Inc. is a clinical-stage biotechnology company advancing novel therapeutics identified using its proprietary computational drug discovery platform. Sinopia’s discovery platform combines high-throughput omics data, machine learning, and network biology. Sinopia is headquartered at JLABS San Diego.

Copyright: 
Copyright Business Wire 2021